Patients

You've been managing T1D. We're working to change it

Man with glasses sitting on a couch checking his blood glucose with a handheld meter

Changing the course of type 1 diabetes (T1D), not just managing symptoms.

Most treatments help people manage the symptoms of T1D. SAB-142 is an investigational therapy being studied to address the underlying autoimmune attack that destroys insulin-producing beta cells, with the potential to change the course of the disease.

Father and young daughter laughing together at home

We’re working to change the course of T1D.

Today’s treatments replace the insulin your body can no longer make. While essential, insulin therapy can’t match the way your body naturally regulates blood sugar or stop the autoimmune attack that destroys insulin-producing beta cells.

Dotted world map

T1D affects millions of people worldwide. In the US, approximately 2 million people are living with insulin-dependent, symptomatic T1D with roughly 64,000 new diagnoses each year.1,2

T1D is an autoimmune disease that affects millions of people worldwide.

In T1D, the immune system—your body’s natural defense against infection—attacks the beta cells in the pancreas that make insulin. This attack on insulin-producing cells results in a reduced capacity to secrete insulin after a meal, resulting in high, uncontrolled blood glucose. For decades, treatment has focused almost entirely on replacing insulin without addressing the underlying cause of the disease.

SAB-142 is an investigational therapy designed to address the underlying autoimmune attack.

SAB-142 is thought to work by targeting multiple immune cells involved in destroying the beta cells that produce insulin with the goal of delaying progression of T1D.

SAB-142 potentially supports long-term disease modification through repeat dosing.

SAB-142 is a fully human antibody therapy. Because they are human antibodies, your immune system is less likely to react against them, unlike reengineered or non-human sources. That means SAB-142 may be suitable for repeat dosing in order to delay progression of T1D.

Illustration of Y-shaped antibody molecules formed from blue and orange particles

SAB-142 is an investigational disease-modifying therapy currently being evaluated in the pivotal SAFEGUARD study as well as the investigator-led Phase 3 PRISE-hATG study.3,4

Two researchers in lab coats reviewing information on a tablet

Explore a clinical trial for newly diagnosed Stage 3 T1D

The SAFEGUARD study is advancing research on SAB-142 in people newly diagnosed with Stage 3 T1D to explore its potential to preserve insulin-producing cells and delay progression of T1D.

Learn more about the SAFEGUARD study


If you’re in the United States, you may contact 1-844-763-1890 or SAFEGUARD@sab.bio for more information.

Not newly diagnosed?
There may still be a path

The investigator-led Phase 3 PRISE-hATG study is exploring SAB-142 in people diagnosed with T1D up to 2 years from diagnosis.

Learn more about the PRISE study

Woman helping a young girl check her blood sugar while sitting together on couch

Get additional T1D education, resources, and community support

Discover our expanded
access policy

References: 1. Rogers MAM, Kim C, Banerjee T, Lee JM. Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study. BMC Med. 2017;15(1):199. doi:10.1186/s12916-017-0958-6 2. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Updated March 11, 2026. Accessed September 10, 2026. https://usdss.cdc.gov/diabetes/report.html 3. SAFety and Efficacy of human anti-thymocyte immunoGlobUlin SAB-142 ARresting progression of type 1 diabetes (SAFEGUARD). ClinicalTrials.gov identifier: NCT07187531. Updated August 24, 2026. Accessed September 10, 2026. https://clinicaltrials.gov/study/NCT07187531 4. PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-peptide preservation in new, recent, and established onset type 1 diabetes treated with human anti-thymocyte globulin [h-ATG]) study (PRISE-hATG). ClinicalTrials.gov identifier: NCT07670650. Updated June 26, 2026. Accessed September 10, 2026. https://clinicaltrials.gov/study/NCT07670650